Modulation of cardiovascular risk factors by obstructive sleep apnea

Chest

Volumn 129, Issue 2, 2006, Pages 218-220

  Olson, Lyle J ^a,b   Somers, Virend K ^a,b  

^a Mayo Clinic and Foundation ^*

^b MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTITHROMBOCYTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CORONARY ARTERY DISEASE; DISEASE ASSOCIATION; EDITORIAL; HUMAN; POSITIVE END EXPIRATORY PRESSURE; PRIORITY JOURNAL; RISK FACTOR; SLEEP APNEA SYNDROME;

EID: 33344473585     PISSN: 00123692     EISSN: None     Source Type: Journal    
DOI: 10.1378/chest.129.2.218     Document Type: Editorial

References (14)

1. American Heart Association. Heart disease and stroke statistics: 2003 update. Dallas, TX: American Heart Association, 2003
2. National Commission on Sleep Disorders Research. Report of the National Commission on Sleep Disorders Research: wake up America; a national sleep alert. Washington, DC: US Government Printing Office, 1995
3. Shahar E, Whitney CW, Redline S, et al. Sleep-disordered breathing and cardiovascular disease: cross-sectional results of the Sleep Heart Health Study. Am J Respir Crit Care Med 2001; 163:19-25
4. Peppard PE, Young T, Palta M, et al. Prospective study of the association between sleep-disordered breathing and hypertension. N Engl J Med 2000; 342:1378-1384
5. Shamsuzzam AS, Gersh BJ, Somers VK. Obstructive sleep apnea: implications for cardiac and vascular disease. JAMA 2003; 290:1906-1914
6. Marin JM, Carrizo SJ, Vicente E, et al. Long-term cardiovascular outcomes in men with obstructive sleep apnea-hypopnea with or without treatment with continuous positive airway pressure: an observational study. Lancet 2005; 365:1046-1053
7. Ridker PM, Wilson PWF, Grundy SM. Should C-reactive protein be added to metabolic syndrome as to assessment of global cardiovascular risk? Circulation 2004; 109:2818-2825
8. Shamsuzzaman ASM, Winnicki MJ, Lanfranchi P, et al. Elevated C-reactive protein in patients with obstructive sleep apnea. Circulation 2002; 105:2462-2464
9. Takuya Y, Kenji M, Hirofumi M, et al. Elevated levels of C-reactive protein and interleukin-6 in patients with obstructive sleep apnea syndrome are decreased by nasal continuous positive airway pressure. Circulation 2003; 107:1129-1133
10. Larkin EK, Rosen CL, Kirchner HL, et al. Variation of C-reactive protein levels in adolescents: association with sleep disordered breathing and sleep duration. Circulation 2005; 111:1978-1984
11. Svatikova A, Wolk R, Magera MJ, et al. Plasma homocysteine in obstructive sleep apnea. Eur Heart J 2004; 25:1325-1329
12. Lavie L, Perelman A, Lavie P. Plasma homocysteine levels in obstructive sleep apnea: association with cardiovascular morbidity. Chest 2001; 120:900-908
13. Jordan W, Berger C, Cohrs S, et al. CPAP-therapy effectively lowers serum homocysteine in obstructive sleep apnea syndrome. J Neural Transm 2004; 111:683-689
14. Can M, Aciköz S, Mungan G, et al. Serum cardiovascular risk factors in obstructive sleep apnea. Chest 2006; 129:233-237